Advances in™ Cardiology: Emerging Treatments for Hypercholesteremia in Statin Intolerant Patient Populations: What Options Do You Have?

Target Audience
This online educational activity is directed toward cardiologists, specialty NPs and PAs, and primary care physicians engaged in the care of patients with hypercholesteremia.

Program Overview
This online educational activity is designed to provide expert interpretation of new and emerging data on the treatment of statin-resistant hypercholesterolemia, with a forward-looking perspective on how novel agents might impact clinical practice. The emerging therapies for treating patients with hypercholesterolemia will be presented in a multimedia format, including a series of video interviews with an expert thought leader integrated into text-based elements.

Statins are the cornerstone pharmacologic therapy to manage hypercholesterolemia, but a relatively large segment of patients with hypercholesterolemia remain at residual risk of cardiovascular disease despite use of these agents. This may be due, in part, to statin intolerance and to the severity of cholesterol elevation, as seen in patients with familial hypercholesterolemia (FH). Newer, nonstatin therapies are now available. These include PCSK9 inhibitors, cholesterol absorption inhibitors (eg, ezetimibe), bempedoic acid, and inclisiran.

Learning Objectives
Upon completion of this activity, participants should be better able to:

Identify appropriate patients who require non-statin therapies for hypercholesterolemia, based on recent guidelines
Describe the efficacy and safety of approved and emerging non-statin drugs for hypercholesterolemia
Characterize the mechanism of action of approved and emerging non-statin drugs for hypercholesterolemia
Explain common barriers to patient adherence to cholesterol-lowering therapy and approaches to identifying and addressing barriers